Clinical activity of venetoclax monotherapy is modest in AML [13], which may partially be explained by the genetic heterogeneity of AML, and more importantly by the heterogeneous and concurrent expression of multiple anti-apoptotic BCL-2 family proteins in AML, and the selectivity of venetoclax for BCL-2 [14]. Here, BCL2 is linked to acute myeloid leukemia.